Tissue kallikrein: A potential serum biomarker to predict delayed cerebral ischemia in aneurysmal subarachnoid hemorrhage

Bian, Lin; Shen, Feng; Mao, Liangang; Zhou, Wei; Zheng, Li; Guanglie, Chen

doi:10.1016/j.cca.2019.12.014

Cited by 4 publications

(4 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Serum Kallikrein (KLK) emerges as a potential biomarker for assessing hemorrhagic severity and predicting DCI following aSAH. 79 A reference interval for KLK6 was established by using serum samples ( n = 136) from an adult population. Additionally, serum samples ( n = 326) from patients with aSAH ( n = 13) were collected for 5–14 days, to study the concentration of KLK6 in this disease.…”

Section: Glucosementioning

confidence: 99%

Biomarkers in aneurysmal subarachnoid hemorrhage: A short review

Batista

Bocanegra-Becerra

Claassen

et al. 2023

World Neurosurgery: X

View full text Add to dashboard Cite

Section: Glucosementioning

confidence: 99%

Biomarkers in aneurysmal subarachnoid hemorrhage: A short review

Batista

Bocanegra-Becerra

Claassen

et al. 2023

World Neurosurgery: X

View full text Add to dashboard Cite

“…Table 1 (Ref. [19][20][21][22][23][24][25][26][27][28][29]) summarizes the degradomic profile of aSAH regarding the prediction of severity and clinical outcome. Degradomics related to vasospasm are summarized in Table 2 (Ref.…”

Section: Degradomicsmentioning

confidence: 99%

“…In [23] enrolled 92 patients with aSAH and 92 healthy controls. KLK6 was found significantly decreased in patients with higher WFNS and modified Fisher scores.…”

Section: Kallikreinmentioning

confidence: 99%

“…Both of these studies [23,27] have shown promising results regarding the potential use of KLK6 to predict clinical outcomes and guide the therapeutic approach. Due to the small number of patients involved in both studies, more prospective studies involving a more significant number of patients should be conducted to better assess its performance.…”

Section: Kallikreinmentioning

confidence: 99%

See 1 more Smart Citation

Clinical utility of degradomics as predictors of complications and clinical outcome in aneurysmal subarachnoid hemorrhage

Bsat

Chanbour

Bsat

et al. 2021

Journal of Integrative Neuroscience

View full text Add to dashboard Cite

Most of the debilitating conditions following aneurysmal subarachnoid hemorrhage result from symptomatic cerebral vasospasm and delayed cerebral ischemia. Several scales are being used, but they still lack objectivity and fail to quantify complications considered essential for prognostication routine use of biomarkers to predict complications and outcomes after aneurysmal rupture is still experimental. Degradomics were studied extensively in traumatic brain injury, but there is no discussion of these biomarkers related to aneurysmal subarachnoid hemorrhage. Degradomics involve the activation of proteases that target specific substrates and generate specific protein fragments called degradomes. While the proteolytic activities constitute the pillar of development, growth, and regeneration of tissues, dysregulated proteolysis resulting from pathological conditions like aneurysmal subarachnoid hemorrhage ends up in apoptotic processes and necrosis. To our knowledge, this is the first overview that lists a panel of degradomics with cut-off values in serum and cerebrospinal fluid, where specificity and sensitivity are only found in Kallikrein 6, Ubiquitin C Terminal Hydrolase 1 and Alpha-II-Spectrin.

show abstract